心泰医疗2025年度报告

Stock Code 股份代號 : 2291 年 度 報 告Annual Report2025 Contents Definitions Definitions Definitions Definitions Corporate Information BOARD OF DIRECTORS Executive DirectorMs. Chen Juan(Chairman) Non-Executive Directors Ms. ZHANG YuxinMr. FU ShanMr. ZHU Guanfu Independent Non-Executive Directors Ms. Chan Ka Lai VanessaMr. Zheng YufengMr. ZHENG Junwei SUPERVISORS 20255 1120255 11 Mr. Wang Xinglin (appointment ceased on May 11, 2025)Ms. Wang Yong(appointed on May 11, 2025,effectiveness subject to Shareholders’ approval)Ms. Wang XiaoyongMr. Qian Weidong AUDIT COMMITTEE Ms. Chan Ka Lai Vanessa(Chairperson)Mr. Zhu GuanfuMr. Zheng Yufeng REMUNERATION COMMITTEE Mr. Zheng Yufeng(Chairperson)Ms. Chen JuanMr. Fu ShanMs. Chan Ka Lai VanessaMr. Zheng Junwei Corporate Information NOMINATION COMMITTEE Ms. Chen Juan(Chairperson)Mr. Zhu GuanfuMs. Chan Ka Lai VanessaMr. Zheng YufengMr. Zheng Junwei JOINT COMPANY SECRETARIES Mr. Qin XueMr. Li Kin Wai(resigned on December 30, 2025)Ms. Yeung Lai Shan(appointed on December 30, 2025) 202512 30202512 30 AUTHORIZED REPRESENTATIVES Ms. Chen JuanMr. Li Kin Wai(resigned on December 30, 2025)Ms. Yeung Lai Shan(appointed on December 30, 2025) 202512 30202512 30 LEGAL ADDRESS IN THE PRC 25841201 Room 201Building 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC ADDRESS OF HEAD OFFICE IN THE PRC 2584115 1/F, 5/FBuilding 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 33191918 Room 1918, 19/F, Lee Garden One33 Hysan AvenueCauseway Bay, Hong Kong Corporate Information AUDITORS BDO China Shu Lun Pan Certified Public Accountants LLP LEGAL ADVISORS As to Hong Kong lawWilson Sonsini Goodrich & Rosati ••• As to PRC law Haiwen & Partners HONG KONG SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKS Bank of ShanghaiChina Merchants BankIndustrial and Commercial Bank of ChinaBank of Ningbo http://www.scientechmed.com/ COMPANY WEBSITE http://www.scientechmed.com/ 2022118 LISTING DATE November 8, 2022 STOCK CODE 22912291 Financial Highlights –Revenue increased by 11.9% from RMB471.6 million forthe year ended December 31, 2024 to RMB527.9 millionfor the year ended December 31, 2025. 20241231471.611.9%20251231527.9 20241231424.05.4%20251231447.0 –Gross profit increased by 5.4% from RMB424.0 million forthe year ended December 31, 2024 to RMB447.0 millionfor the year ended December 31, 2025. 2024123158.00.3%2025123158.1 –Research and development expenses increased by 0.3%from RMB58.0 million for the year ended December 31,2024 to RMB58.1 million for the year ended December 31,2025. 20241231245.62.4%20251231239.7 –Netprofit attributable to shareholders of the parentcompany decreased by 2.4% from RMB245.6 million forthe year ended December 31, 2024 to RMB239.7 millionfor the year ended December 31, 2025. 202512310.5202412310.62 –The Board recommends the payment of a final dividendof RMB0.5 per Share (tax inclusive) for the year endedDecember31,2025(a final dividend of RMB0.62 perShare(tax inclusive)for the year ended December 31,2024). Note: Certain amounts and percentage figures included in this annual reporthave been subject to rounding. Accordingly, figures shown as totalsin certain tables may not be an arithmetic aggregation of the figurespreceding them. Any discrepancies in any table or chart between thetotal shown and the sum of the amounts listed are due to rounding. Chairman’s Statement DearShareholders,partners and all colleagues of ScienTechMedical: On behalf of the Board and all employees of ScienTech Medical,I would like to extend my sincerest gratitude with best wishes toour Shareholders, investors, partners and friends from all walksof life who have long cared for and supported the developmentof the Company! 2025 The year 2025 was a year for the Company to face difficultiesand make steady progress. In the face of the dual challenges ofindustry policy adjustments and intensified market competition,theCompany has consistently adhered to the strategicpolicyof“innovation-driven,quality-first,and internationalizeddevelopment”,and achieved steady growth in revenueandgross profit by virtue of solid technological expertise,comprehensiveproduct matrix,and efficient operation andmanagement. Making Steady Progress to Steadily Improve OperationalQuality and Efficiency In 2025, the Company achieved revenue of RMB527.9 million,representinga year-on-year increase of 11.9%;gross profitreachedRMB447.0 million,representing a year-on-yearincreaseof 5.4%;and cash flows from operating activitiesremained healthy. By the end of the year, the Company’s totalassets and net assets steadily increased, and the gearing ratiomaintainedat a low level,demonstrating a sound and solidfinancialstructure.Affected by the centralized procurementorganized by Fujian Provincial Healthcare Security Bureau (),the performance of occluders in the